WO2019072051A1 - Traditional chinese medicine extract with anti-depressive effect and preparation method and application thereof - Google Patents
Traditional chinese medicine extract with anti-depressive effect and preparation method and application thereof Download PDFInfo
- Publication number
- WO2019072051A1 WO2019072051A1 PCT/CN2018/103870 CN2018103870W WO2019072051A1 WO 2019072051 A1 WO2019072051 A1 WO 2019072051A1 CN 2018103870 W CN2018103870 W CN 2018103870W WO 2019072051 A1 WO2019072051 A1 WO 2019072051A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- chinese medicine
- paste
- traditional chinese
- water
- extract
- Prior art date
Links
- 239000003814 drug Substances 0.000 title claims abstract description 55
- 239000000284 extract Substances 0.000 title claims abstract description 52
- 230000001430 anti-depressive effect Effects 0.000 title claims abstract description 20
- 238000002360 preparation method Methods 0.000 title claims abstract description 11
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims abstract description 57
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims abstract description 34
- 239000000706 filtrate Substances 0.000 claims abstract description 12
- 239000000203 mixture Substances 0.000 claims abstract description 11
- 241000132012 Atractylodes Species 0.000 claims abstract description 7
- 239000006228 supernatant Substances 0.000 claims abstract description 7
- 238000001914 filtration Methods 0.000 claims abstract description 6
- 244000246386 Mentha pulegium Species 0.000 claims abstract description 4
- 235000016257 Mentha pulegium Nutrition 0.000 claims abstract description 4
- 235000004357 Mentha x piperita Nutrition 0.000 claims abstract description 4
- 235000001050 hortel pimenta Nutrition 0.000 claims abstract description 4
- 235000001287 Guettarda speciosa Nutrition 0.000 claims description 10
- 241000202726 Bupleurum Species 0.000 claims description 8
- 239000008187 granular material Substances 0.000 claims description 8
- 239000012141 concentrate Substances 0.000 claims description 7
- 238000000605 extraction Methods 0.000 claims description 7
- 239000000463 material Substances 0.000 claims description 6
- 241000202807 Glycyrrhiza Species 0.000 claims description 5
- 244000236658 Paeonia lactiflora Species 0.000 claims description 5
- 235000008598 Paeonia lactiflora Nutrition 0.000 claims description 5
- 244000221633 Brassica rapa subsp chinensis Species 0.000 claims description 2
- 235000010149 Brassica rapa subsp chinensis Nutrition 0.000 claims description 2
- 235000006679 Mentha X verticillata Nutrition 0.000 claims description 2
- 235000002899 Mentha suaveolens Nutrition 0.000 claims description 2
- 235000001636 Mentha x rotundifolia Nutrition 0.000 claims description 2
- 238000009826 distribution Methods 0.000 claims description 2
- 239000006072 paste Substances 0.000 claims description 2
- 240000002045 Guettarda speciosa Species 0.000 claims 3
- 238000000034 method Methods 0.000 abstract description 7
- 235000006200 Glycyrrhiza glabra Nutrition 0.000 abstract description 4
- 241000213006 Angelica dahurica Species 0.000 abstract 1
- 244000236521 Bupleurum rotundifolium Species 0.000 abstract 1
- 235000015221 Bupleurum rotundifolium Nutrition 0.000 abstract 1
- 244000303040 Glycyrrhiza glabra Species 0.000 abstract 1
- 235000017443 Hedysarum boreale Nutrition 0.000 abstract 1
- 235000007858 Hedysarum occidentale Nutrition 0.000 abstract 1
- 244000170916 Paeonia officinalis Species 0.000 abstract 1
- 235000006484 Paeonia officinalis Nutrition 0.000 abstract 1
- 239000001947 glycyrrhiza glabra rhizome/root Substances 0.000 abstract 1
- 235000012907 honey Nutrition 0.000 abstract 1
- 238000002156 mixing Methods 0.000 abstract 1
- 238000010298 pulverizing process Methods 0.000 abstract 1
- 239000013049 sediment Substances 0.000 abstract 1
- 238000007873 sieving Methods 0.000 abstract 1
- 235000015099 wheat brans Nutrition 0.000 abstract 1
- 241000700159 Rattus Species 0.000 description 41
- 230000000694 effects Effects 0.000 description 18
- 239000000935 antidepressant agent Substances 0.000 description 14
- PNVNVHUZROJLTJ-UHFFFAOYSA-N venlafaxine Chemical compound C1=CC(OC)=CC=C1C(CN(C)C)C1(O)CCCCC1 PNVNVHUZROJLTJ-UHFFFAOYSA-N 0.000 description 13
- 239000012676 herbal extract Substances 0.000 description 10
- 229960004688 venlafaxine Drugs 0.000 description 10
- 229940005513 antidepressants Drugs 0.000 description 9
- 229940079593 drug Drugs 0.000 description 9
- 238000002474 experimental method Methods 0.000 description 9
- 241000125175 Angelica Species 0.000 description 7
- 230000037396 body weight Effects 0.000 description 7
- 210000002784 stomach Anatomy 0.000 description 7
- 208000019901 Anxiety disease Diseases 0.000 description 5
- 241001465754 Metazoa Species 0.000 description 5
- 238000010171 animal model Methods 0.000 description 5
- 230000036506 anxiety Effects 0.000 description 5
- 230000003247 decreasing effect Effects 0.000 description 5
- 210000003608 fece Anatomy 0.000 description 5
- 230000035946 sexual desire Effects 0.000 description 5
- 208000024891 symptom Diseases 0.000 description 5
- 230000009193 crawling Effects 0.000 description 4
- 229940000406 drug candidate Drugs 0.000 description 4
- 239000003777 experimental drug Substances 0.000 description 4
- 235000008216 herbs Nutrition 0.000 description 4
- 210000000813 small intestine Anatomy 0.000 description 4
- 238000012360 testing method Methods 0.000 description 4
- NOOLISFMXDJSKH-UTLUCORTSA-N (+)-Neomenthol Chemical compound CC(C)[C@@H]1CC[C@@H](C)C[C@@H]1O NOOLISFMXDJSKH-UTLUCORTSA-N 0.000 description 3
- NOOLISFMXDJSKH-UHFFFAOYSA-N DL-menthol Natural products CC(C)C1CCC(C)CC1O NOOLISFMXDJSKH-UHFFFAOYSA-N 0.000 description 3
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 3
- 235000001453 Glycyrrhiza echinata Nutrition 0.000 description 3
- 235000017382 Glycyrrhiza lepidota Nutrition 0.000 description 3
- 229930006000 Sucrose Natural products 0.000 description 3
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 3
- 230000005856 abnormality Effects 0.000 description 3
- 230000000994 depressogenic effect Effects 0.000 description 3
- 239000012153 distilled water Substances 0.000 description 3
- 230000002496 gastric effect Effects 0.000 description 3
- 230000030136 gastric emptying Effects 0.000 description 3
- 230000007661 gastrointestinal function Effects 0.000 description 3
- 230000000968 intestinal effect Effects 0.000 description 3
- 230000013016 learning Effects 0.000 description 3
- 229940010454 licorice Drugs 0.000 description 3
- 229940041616 menthol Drugs 0.000 description 3
- 239000007787 solid Substances 0.000 description 3
- 239000005720 sucrose Substances 0.000 description 3
- 238000011282 treatment Methods 0.000 description 3
- 206010010774 Constipation Diseases 0.000 description 2
- 208000020401 Depressive disease Diseases 0.000 description 2
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 2
- RJKFOVLPORLFTN-LEKSSAKUSA-N Progesterone Chemical compound C1CC2=CC(=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H](C(=O)C)[C@@]1(C)CC2 RJKFOVLPORLFTN-LEKSSAKUSA-N 0.000 description 2
- 239000002131 composite material Substances 0.000 description 2
- 235000008504 concentrate Nutrition 0.000 description 2
- 230000007423 decrease Effects 0.000 description 2
- 238000001125 extrusion Methods 0.000 description 2
- 230000006870 function Effects 0.000 description 2
- 238000009776 industrial production Methods 0.000 description 2
- 230000007246 mechanism Effects 0.000 description 2
- 230000008897 memory decline Effects 0.000 description 2
- 235000015097 nutrients Nutrition 0.000 description 2
- 230000000144 pharmacologic effect Effects 0.000 description 2
- 239000000843 powder Substances 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 230000000638 stimulation Effects 0.000 description 2
- 238000003809 water extraction Methods 0.000 description 2
- VOXZDWNPVJITMN-ZBRFXRBCSA-N 17β-estradiol Chemical compound OC1=CC=C2[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CCC2=C1 VOXZDWNPVJITMN-ZBRFXRBCSA-N 0.000 description 1
- 208000028698 Cognitive impairment Diseases 0.000 description 1
- 229920001353 Dextrin Polymers 0.000 description 1
- 239000004375 Dextrin Substances 0.000 description 1
- 206010013710 Drug interaction Diseases 0.000 description 1
- 229920000881 Modified starch Polymers 0.000 description 1
- 238000012347 Morris Water Maze Methods 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- 235000019485 Safflower oil Nutrition 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 230000001476 alcoholic effect Effects 0.000 description 1
- 230000037007 arousal Effects 0.000 description 1
- 230000006399 behavior Effects 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 210000002318 cardia Anatomy 0.000 description 1
- 208000010877 cognitive disease Diseases 0.000 description 1
- 230000003920 cognitive function Effects 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 235000019425 dextrin Nutrition 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 230000003828 downregulation Effects 0.000 description 1
- 239000003640 drug residue Substances 0.000 description 1
- 238000002651 drug therapy Methods 0.000 description 1
- 238000007908 dry granulation Methods 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 229960005309 estradiol Drugs 0.000 description 1
- 229930182833 estradiol Natural products 0.000 description 1
- 230000012173 estrus Effects 0.000 description 1
- 230000002550 fecal effect Effects 0.000 description 1
- 230000005176 gastrointestinal motility Effects 0.000 description 1
- 238000005469 granulation Methods 0.000 description 1
- 230000003179 granulation Effects 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 241000411851 herbal medicine Species 0.000 description 1
- 239000005457 ice water Substances 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 239000012535 impurity Substances 0.000 description 1
- 238000011835 investigation Methods 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 230000013011 mating Effects 0.000 description 1
- 235000012054 meals Nutrition 0.000 description 1
- 230000010534 mechanism of action Effects 0.000 description 1
- 230000007721 medicinal effect Effects 0.000 description 1
- 230000002503 metabolic effect Effects 0.000 description 1
- VYQNWZOUAUKGHI-UHFFFAOYSA-N monobenzone Chemical compound C1=CC(O)=CC=C1OCC1=CC=CC=C1 VYQNWZOUAUKGHI-UHFFFAOYSA-N 0.000 description 1
- 238000012346 open field test Methods 0.000 description 1
- 239000008188 pellet Substances 0.000 description 1
- 230000000149 penetrating effect Effects 0.000 description 1
- 230000008855 peristalsis Effects 0.000 description 1
- 239000003208 petroleum Substances 0.000 description 1
- 230000003285 pharmacodynamic effect Effects 0.000 description 1
- 238000000554 physical therapy Methods 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 229960003387 progesterone Drugs 0.000 description 1
- 239000000186 progesterone Substances 0.000 description 1
- 238000001671 psychotherapy Methods 0.000 description 1
- 210000001187 pylorus Anatomy 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 235000005713 safflower oil Nutrition 0.000 description 1
- 239000003813 safflower oil Substances 0.000 description 1
- 230000009329 sexual behaviour Effects 0.000 description 1
- 230000036299 sexual function Effects 0.000 description 1
- 230000035939 shock Effects 0.000 description 1
- 229910001220 stainless steel Inorganic materials 0.000 description 1
- 239000010935 stainless steel Substances 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 230000009182 swimming Effects 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 238000012549 training Methods 0.000 description 1
- 238000002604 ultrasonography Methods 0.000 description 1
- 229960002416 venlafaxine hydrochloride Drugs 0.000 description 1
- QYRYFNHXARDNFZ-UHFFFAOYSA-N venlafaxine hydrochloride Chemical compound [H+].[Cl-].C1=CC(OC)=CC=C1C(CN(C)C)C1(O)CCCCC1 QYRYFNHXARDNFZ-UHFFFAOYSA-N 0.000 description 1
- 238000005303 weighing Methods 0.000 description 1
- 229940126673 western medicines Drugs 0.000 description 1
- 239000000080 wetting agent Substances 0.000 description 1
- 239000008539 xiaoyao Substances 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/23—Apiaceae or Umbelliferae (Carrot family), e.g. dill, chervil, coriander or cumin
- A61K36/232—Angelica
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/23—Apiaceae or Umbelliferae (Carrot family), e.g. dill, chervil, coriander or cumin
- A61K36/233—Bupleurum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/28—Asteraceae or Compositae (Aster or Sunflower family), e.g. chamomile, feverfew, yarrow or echinacea
- A61K36/284—Atractylodes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/48—Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
- A61K36/484—Glycyrrhiza (licorice)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/53—Lamiaceae or Labiatae (Mint family), e.g. thyme, rosemary or lavender
- A61K36/534—Mentha (mint)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/65—Paeoniaceae (Peony family), e.g. Chinese peony
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/71—Ranunculaceae (Buttercup family), e.g. larkspur, hepatica, hydrastis, columbine or goldenseal
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
Definitions
- the invention belongs to the field of Chinese medicine extraction, and particularly relates to a traditional Chinese medicine extract with antidepressant effect, a preparation method and application thereof.
- Xiaoyao San is a classic Chinese medicine prescription for soothing the liver and relieving depression.
- the two authorized patents of this research group (201010110283.7 and 201110084715.6) extracted with ethyl acetate and petroleum ether, indicating that Xiaoyao San has a clear anti-depression effect, but on the one hand, industrial production has many safety hazards, and the process controllability is poor; Xiaoyao Sanyuan prescription has more medicinal materials, and the dosage is relatively large, and the quality is not easy to control. Therefore, based on the research on Xiaoyao San, the present invention prepares a traditional Chinese medicine extract by using the alcoholic water extraction method which is simpler in composition and more suitable for the pilot production, and studies the antidepressant effect characteristics.
- the object of the present invention is to provide a traditional Chinese medicine extract with simple composition, scientific and reasonable technology, and a plurality of medicinal properties with significant improvement in depression, and a preparation process and application thereof.
- the invention provides a traditional Chinese medicine extract with antidepressant effect, which is characterized by a distribution ratio and a preparation method of the traditional Chinese medicine group:
- the traditional Chinese medicine component is in terms of mass parts: Bupleurum 20-60, Angelica 20-60, bran-frying atractylodes 20-60, white peony 20-60, mint 8-20, licorice licorice 8-20;
- the preparation method comprises the following steps: 1) adding 6-10 times weight of 60-90% ethanol to the component medicine, extracting twice, each time 1-3 h, filtering, combining the filtrate, and concentrating to obtain alcohol extract 2)
- the dregs are added with 6-10 times the weight of water for 2 times, each time 1-3h, filtered, the filtrate is combined, concentrated to obtain a water extracting paste, and ethanol is added to the water extracting paste to make the alcohol content Up to 60-80%, let stand for 24h, take the supernatant, concentrate to clear the paste; 3) combine the clear paste with the alcohol extract paste, mix and concentrate to thick paste, dry under microwave pressure, smash through 80 mesh sieve , that is, the Chinese medicine extract.
- the components are preferably: Bupleurum 30, Angelica 30, Brassica chinensis 30, Angelica 30, Peppermint 10, and Zhigancao 15 in parts by mass.
- the weight of the ethanol added in the step 1) is 8 times the weight of the medicinal material, the ethanol concentration is 75%, and the extraction time is 2 hours.
- the weight of the added water in the step 2) is 8 times the weight of the medicinal material, and the extraction time is 2 hours.
- Step 3 The water content of the water extracting paste after adding ethanol is 70%.
- the density of the above alcohol extracting paste, water extracting paste and clearing paste is controlled to be 1.08 to 1.10, and the density of the thick paste is controlled to be 1.24 to 1.26.
- the invention provides a traditional Chinese medicine granule comprising the traditional Chinese medicine extract and the auxiliary material and the like as described above.
- the invention provides that the prescription is simpler, the dosage is less, the quality is more controllable, the pharmacological activity reaches or exceeds the listed antidepressant western medicine venlafaxine, the antidepressant traditional Chinese medicine Shugan Jieyu and Xiaoyao San.
- the antidepressant effect is equivalent, and: 1 no venlafaxine-induced constipation, decreased gastrointestinal motility and decreased sexual desire; 2 improved CUMS-depressed rats Learning memory decline and anxiety.
- Figure 1 is a flow chart of the preparation process of the traditional Chinese medicine extract of the present invention
- Venlafaxine hydrochloride Choengdu Kanghong Pharmaceutical Group Co., Ltd., specification: 25mg/granule, batch number: national medicine standard word H20070269
- Stimuli include fasting, water ban, 4°C ice water swimming, 50°C thermal stimulation, tail trapping, intermittent foot shock, restraint, ultrasound stimulation, and day and night reversal.
- One stimulus was randomly given daily, and each stimulus was used 2-3 times cumulatively. Except for the blank control group, the other groups were housed in a single cage and the modeling procedure was carried out. The modeling time was 28 days.
- the drug was administered by intragastric administration. The drug group was given the corresponding concentration of the drug solution, and the model group and the blank control group were given an equal volume of distilled water.
- Body weight Rat body weight was weighed on the 0th, 7th, 14th, 21st, and 28th day of the experiment.
- Rats were placed in the open field box for 5 min, and the number of penetrating and erecting times of the rats within 4 min after recording were recorded.
- Chinese herbal extracts can improve the growth of rat body weight caused by CUMS modeling stress.
- the decrease of activity and the preference for sucrose sweetness indicate that the extract of Chinese medicine has a good antidepressant effect, and its pharmacological activity meets or exceeds the listed antidepressant western medicine venlafaxine and antidepressant Chinese medicine Shugan solution. Yu.
- Gastric residual rate (stomach weight - stomach net weight) / homemade semi-solid nutrient paste weight ⁇ 100%
- Small intestine propulsion rate length of small intestine / distance of self-made semi-solid paste propulsion ⁇ 100%
- Table 4 shows that CUMS stress increases the number of bowel movements in rats and decreases the water content of feces. Compared with venlafaxine, this phenomenon can not be improved and negative regulation is observed.
- Tables 5 and 6 show that modeling stress slows the intestinal peristalsis and gastric emptying function in rats, and venlafaxine has a decreasing trend in the small intestine propulsion rate and intragastric meal rate compared with the model group, suggesting that venlafaxine It may have the effect of reducing gastrointestinal function.
- Chinese herbal extracts can improve gastrointestinal function in rats while treating depression.
- mice 48 h before the experiment, female mice were injected subcutaneously with estradiol 10 ⁇ g (dissolved in 0.1 ml safflower oil); 2 h before the experiment, 10 ⁇ g of progesterone was injected subcutaneously.
- estradiol 10 ⁇ g dissolved in 0.1 ml safflower oil
- progesterone 10 ⁇ g was injected subcutaneously.
- the CUMS male and the estrus female were caged, and at 7-9 pm, the males' sexual behavior was observed within 30 minutes, and the crawling latency and the number of crawling backs were recorded.
- the crawling behavior of male rats in mating experiments can reflect the size of their sexual desire to a certain extent.
- Table 7 shows that CUMS stress prolongs the crawler latency of the rats and reduces the number of crawling backs. To some extent, the arousal of rat sexual desire is affected by the modeling stress. Compared with venlafaxine, this indicator is negatively regulated. After administration of traditional Chinese medicine extract, the abnormality of the above indicators can be improved, indicating that the Chinese herbal extract improves the depression-like symptoms of CUMS rats without causing side effects of libido reduction.
- the Morris water maze and the elevated cross maze experiment were carried out.
- the spatial navigation latency and the number of crossing platforms in the water maze were selected as the investigation of the cognitive function of CUMS rats.
- the number of open arms in the elevated cross maze was selected. Proportion and ratio of time to open arm were used as an examination of anxiety in CUMS rats.
- Table 8 shows that CUMS-depressed rats have a reduced number of crossing platforms and target quadrants during the spatial exploration period, suggesting that CUMS-depressed rats are associated with cognitive impairment. Compared with venlafaxine, this phenomenon can be adjusted, and the Chinese herbal extract can improve this symptom after administration.
- the traditional Chinese medicine extract powder and the pregelatinized starch are mixed in a ratio of 5:2, and are granulated by dry granulation to prepare granules.
- the parameters of the dry granulator are adjusted to: extrusion speed 6.0 rpm; feed speed 7.0 rpm; The pellet speed was 10.0 rpm; the side seal pressure was 13 MPa; the extrusion pressure was 27 MPa.
- the mesh used in the granulation was 10 mesh, and the whole sieve was 40 mesh.
- the granules are granulated and packaged by the composite film to obtain the finished product.
- Chinese herbal extract powder is mixed with sucrose and dextrin in a ratio of 2:0.5:0.5, using 75% ethanol as a wetting agent, swaying granulator, passing through 10 mesh stainless steel mesh, granulating, drying, passing 40 mesh sieve The net is granulated and packaged in a composite film.
Landscapes
- Health & Medical Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Botany (AREA)
- Mycology (AREA)
- Epidemiology (AREA)
- Microbiology (AREA)
- Medical Informatics (AREA)
- Biotechnology (AREA)
- Alternative & Traditional Medicine (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Psychiatry (AREA)
- Pain & Pain Management (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
A traditional Chinese medicine (TCM) extract with an anti-depressive effect and a preparation method and application thereof. The method comprises: collecting, according to a component composition, root of Chinese thorowax, Chinese angelica, largehead atractylodes rhizome stir-fried with wheat bran, white paeony root, peppermint, and licorice root prepared with honey; adding ethanol to extract, filtering, combining filtrates, and concentrating to obtain an ethanol-extracted clear paste; adding water to extract from sediment, filtering, combining filtrates, and concentrating to obtain a water-extracted clear paste; adding ethanol to the water-extracted clear paste, leaving to stand, collecting a supernatant, and concentrating the supernatant into a clear paste; and combining the clear paste and the ethanol-extracted clear paste, mixing and concentrating into a thick paste, microwaving the thick paste to dry under reduced pressure, and pulverizing and sieving to obtain the TCM extract.
Description
本发明属于中药提取领域,具体涉及一种具有抗抑郁功效的中药提取物及其制备方法和应用。The invention belongs to the field of Chinese medicine extraction, and particularly relates to a traditional Chinese medicine extract with antidepressant effect, a preparation method and application thereof.
目前,抑郁症的治疗主要有三种方式:药物治疗、心理治疗和物理治疗,但仍以化学药物治疗为主。上市的抗抑郁化药种类有限,机制单一,有效率不高,尚未超过70%,并且副作用较大,如便秘、性欲降低等,在治疗抑郁症的同时也威胁着患者身体其他功能的健康。临床上在选用西药去治疗抑郁症时候要综合考虑治疗有效率、作用机制、选用剂量、副作用、药物相互作用等因素,并且对于一些复杂的抑郁症如双相多相抑郁、一种或多种疾病和抑郁的共病得不到理想的改善。At present, there are three main treatments for depression: drug therapy, psychotherapy and physical therapy, but still mainly based on chemical drugs. The list of antidepressant drugs listed is limited, the mechanism is single, the efficiency is not high, not more than 70%, and the side effects are large, such as constipation, decreased sexual desire, etc., in the treatment of depression, it also threatens the health of other functions of the patient's body. Clinically, when Western medicine is used to treat depression, comprehensive consideration should be given to the treatment efficiency, mechanism of action, dose selection, side effects, drug interaction and other factors, and for some complex depressions such as bipolar polyphasic depression, one or more Symptoms of disease and depression are not ideally improved.
正是由于现有西药的缺陷和市场需求的紧迫性,国内外学者将目光转移到中草药提取物。如何从中草药中开发在具有明确抗抑郁药效基础上,或有着自己独特药效特点,或有着新型的抗抑郁作用机制,或针对特殊病情,或有着新的适应症,或具备副作用相对较小、多靶点、多功效等功效特点的新型抗抑郁药物,是未来抗抑郁药物研发的大趋势。It is precisely because of the defects of existing western medicines and the urgency of market demand that scholars at home and abroad have turned their attention to Chinese herbal extracts. How to develop from Chinese herbal medicine on the basis of clear anti-depressant efficacy, or have its own unique pharmacodynamic characteristics, or have a new anti-depressant mechanism, or for specific conditions, or have new indications, or have relatively few side effects New antidepressant drugs with multi-target, multi-effect and other features are the major trends in the development of antidepressant drugs in the future.
逍遥散是疏肝解郁的经典中药名方。前期本课题组两项授权专利(201010110283.7和201110084715.6)采用乙酸乙酯和石油醚提取表明逍遥散具有明确的抗抑郁作用,但一方面工业化生产具有诸多安全隐患,工艺可控性较差;一方面逍遥散原方组方药材较多,服用量相对较大,质量不易控制。因此本发明是在对逍遥散的研究基础上,采用组方更加简单、工艺更适合中试生产的醇水提取法制备一种中药提取物,并对其抗抑郁功效特点进行了研究。Xiaoyao San is a classic Chinese medicine prescription for soothing the liver and relieving depression. In the previous period, the two authorized patents of this research group (201010110283.7 and 201110084715.6) extracted with ethyl acetate and petroleum ether, indicating that Xiaoyao San has a clear anti-depression effect, but on the one hand, industrial production has many safety hazards, and the process controllability is poor; Xiaoyao Sanyuan prescription has more medicinal materials, and the dosage is relatively large, and the quality is not easy to control. Therefore, based on the research on Xiaoyao San, the present invention prepares a traditional Chinese medicine extract by using the alcoholic water extraction method which is simpler in composition and more suitable for the pilot production, and studies the antidepressant effect characteristics.
发明内容Summary of the invention
本发明的目的在于提供一种组方简单、工艺科学合理,具有显著改善抑郁症伴发的多项兼症的药效特点中药提取物及其制备工艺和应用。The object of the present invention is to provide a traditional Chinese medicine extract with simple composition, scientific and reasonable technology, and a plurality of medicinal properties with significant improvement in depression, and a preparation process and application thereof.
本发明提供的一种具有抗抑郁功效的中药提取物,其特征在于中药组分配比和制备方法:The invention provides a traditional Chinese medicine extract with antidepressant effect, which is characterized by a distribution ratio and a preparation method of the traditional Chinese medicine group:
所述中药组分按质量份数计为:柴胡20~60、当归20~60、麸炒白术20~60、白芍20~60、薄荷8~20、炙甘草8~20;The traditional Chinese medicine component is in terms of mass parts: Bupleurum 20-60, Angelica 20-60, bran-frying atractylodes 20-60, white peony 20-60, mint 8-20, licorice licorice 8-20;
所述制备方法,包括如下步骤:1)在所述组分药材中加入6-10倍重量的60~90%乙醇提取2次,每次1-3h,滤过,合并滤液,浓缩得醇提清膏;2)药渣加入6-10倍重量的水提取2次,每次1-3h,滤过,合并滤液,浓缩得水提清膏,在水提清膏中加入乙醇使含醇量达60~80%,静置24h,取上清液,浓缩至清膏;3)将清膏与醇提清膏合并,混匀后浓缩至稠膏,微波减压干燥,粉碎过80目筛,即得中药提取物。The preparation method comprises the following steps: 1) adding 6-10 times weight of 60-90% ethanol to the component medicine, extracting twice, each time 1-3 h, filtering, combining the filtrate, and concentrating to obtain alcohol extract 2) The dregs are added with 6-10 times the weight of water for 2 times, each time 1-3h, filtered, the filtrate is combined, concentrated to obtain a water extracting paste, and ethanol is added to the water extracting paste to make the alcohol content Up to 60-80%, let stand for 24h, take the supernatant, concentrate to clear the paste; 3) combine the clear paste with the alcohol extract paste, mix and concentrate to thick paste, dry under microwave pressure, smash through 80 mesh sieve , that is, the Chinese medicine extract.
所述组分按质量份数计优选为:柴胡30、当归30、麸炒白术30、白芍30、薄荷10、炙甘草15。The components are preferably: Bupleurum 30, Angelica 30, Brassica chinensis 30, Angelica 30, Peppermint 10, and Zhigancao 15 in parts by mass.
步骤1)中所述加入乙醇的重量为药材重量的8倍,乙醇浓度为75%,每次提取时间为2h。The weight of the ethanol added in the step 1) is 8 times the weight of the medicinal material, the ethanol concentration is 75%, and the extraction time is 2 hours.
步骤2)中所述加入水的重量为药材重量的8倍,每次提取时间为2h。The weight of the added water in the step 2) is 8 times the weight of the medicinal material, and the extraction time is 2 hours.
步骤3)中水提清膏加入乙醇后的含醇量为70%。Step 3) The water content of the water extracting paste after adding ethanol is 70%.
上述醇提清膏、水提清膏、清膏的密度控制在1.08~1.10,稠膏密度控制在1.24~1.26。The density of the above alcohol extracting paste, water extracting paste and clearing paste is controlled to be 1.08 to 1.10, and the density of the thick paste is controlled to be 1.24 to 1.26.
如上所述的中药提取物经实验证明具有明显的抗抑郁功效,其可在制备治疗抑郁症药物中应用。The traditional Chinese medicine extract as described above has been experimentally proven to have significant antidepressant effects, which can be applied in the preparation of a medicament for treating depression.
本发明提供的一种中药颗粒剂,含有如上所述的中药提取物和辅料等。The invention provides a traditional Chinese medicine granule comprising the traditional Chinese medicine extract and the auxiliary material and the like as described above.
本发明具有如下优点:The invention has the following advantages:
1、本发明提供组方相比逍遥散更加简单、服用剂量更少、质量更加可控,药理活性达到或超过上市抗抑郁西药文拉法辛、抗抑郁中药舒肝解郁及逍遥散。1. The invention provides that the prescription is simpler, the dosage is less, the quality is more controllable, the pharmacological activity reaches or exceeds the listed antidepressant western medicine venlafaxine, the antidepressant traditional Chinese medicine Shugan Jieyu and Xiaoyao San.
2、采用工艺更加合理安全、更易于中试工业化生产的醇水提取法,最大程度、更加全面地提取有效成分,去除杂质,降低出膏率以减轻了患者服用剂量。2, the use of more reasonable and safe process, easier to pilot industrial production of alcohol water extraction method, the maximum extent, more comprehensive extraction of active ingredients, remove impurities, reduce the rate of extraction to reduce the dosage of patients.
3、与临床常用抗抑郁西药文拉法辛相比,抗抑郁作用相当,且:①无文拉法辛引起的便秘、胃肠动力下降和性欲降低副作用;②改善CUMS抑郁大鼠伴发的学习记忆能力下降和焦虑情绪。3. Compared with the commonly used antidepressant western medicine venlafaxine, the antidepressant effect is equivalent, and: 1 no venlafaxine-induced constipation, decreased gastrointestinal motility and decreased sexual desire; 2 improved CUMS-depressed rats Learning memory decline and anxiety.
图1本发明中药提取物的制备工艺流程图Figure 1 is a flow chart of the preparation process of the traditional Chinese medicine extract of the present invention
为了对本发明进行更进一步的详细描述,给出以下具体实施例,但仅作为阐明本发明,而不是为了限制本发明的保护范围。The following specific examples are set forth to illustrate the invention, but are not intended to limit the scope of the invention.
实施例1Example 1
按质量份数称取柴胡30份、当归30份、麸炒白术30份、白芍30份、薄荷10份、炙甘草15份,加入8倍重量的75%乙醇提取2次,每次2h,滤过,合并滤液,浓缩至相对密度为1.09的醇提清膏;药渣加入8倍重量的水提取2次,每次2h,滤过,合并滤液,浓缩至相对密度为1.09的水提清膏;在水提清膏中加入乙醇使含醇量达70%,静置24h(4℃),取上清液浓缩至相对密度为1.09的清膏,与醇提清膏合并,混匀后浓缩至相对密度为1.25的稠膏,微波减压干燥,得到干浸膏,粉碎,过80目筛,即得。Weigh 30 parts of Bupleurum, 30 parts of Angelica, 30 parts of bran atractylodes, 30 parts of white peony, 10 parts of menthol, 15 parts of licorice, and add 8 times of 75% ethanol for 2 times, 2h each time. After filtration, the filtrate was combined and concentrated to an alcohol extracting paste having a relative density of 1.09; the dregs were added to 8 times by weight of water for 2 times, each time for 2 hours, filtered, and the filtrate was concentrated to a water having a relative density of 1.09. Clear the paste; add ethanol to the water extract paste to make the alcohol content up to 70%, let stand for 24h (4 ° C), take the supernatant to concentrate to a relative density of 1.09 clear paste, and mix with the alcohol extract paste, mix After concentration, it is concentrated to a thick paste having a relative density of 1.25, and dried under reduced pressure in a microwave to obtain a dry extract, which is pulverized and passed through a sieve of 80 mesh.
实施例2Example 2
按质量份数称取柴胡30份、当归30份、麸炒白术20份、白芍20份、薄荷10份、炙甘草15份,加入8倍重量的60%乙醇提取2次,每次2h,滤过,合并滤液,浓缩至相对密度为1.08的醇提清膏;药渣加入8倍重量的水提取2次,每次2h,滤过,合并滤液,浓缩至相对密度为1.08的水提清膏;在水提清膏中加入乙醇使含醇量达60%,静置24h(4℃),取上清液浓缩至相对密度为1.08的清膏,与醇提清膏合并,混匀后浓缩至相对密度为1.24的稠膏,微波减压干燥,得到干浸膏,粉碎,过80目筛,即得。Weigh 30 parts of Bupleurum, 30 parts of Angelica, 20 parts of braised atractylodes, 20 parts of white peony, 10 parts of menthol, 15 parts of licorice, and add 2 times of 60% ethanol for 2 times, 2h each time. After filtration, the filtrate was combined and concentrated to an alcohol extract with a relative density of 1.08; the dregs were added to 8 times by weight of water for 2 times, each time for 2 h, filtered, and the filtrate was concentrated to a water density of 1.08. Clear the paste; add ethanol to the water extract paste to make the alcohol content up to 60%, let stand for 24h (4 ° C), take the supernatant to concentrate to a relative density of 1.08, and mix with the alcohol extract paste, mix After concentration, it was concentrated to a thick paste having a relative density of 1.24, and dried under reduced pressure in a microwave to obtain a dry extract, which was pulverized and passed through a sieve of 80 mesh.
实施例3Example 3
按质量份数称取柴胡30份、当归30份、麸炒白术30份、白芍20份、薄荷10份、炙甘草15份,加入8倍重量的90%乙醇提取2次,每次2h,滤过,合并滤液,浓缩至相对密度为1.10的醇提清膏;药渣加入8倍重量的水提取2次,每次2h,滤过,合并滤液,浓缩至相对密度为1.10的水提清膏;在水提清膏中加入乙醇使含醇量达80%,静置24h(4℃),取上清液浓缩至相对密度为1.10的清膏,与醇提清膏合并,混匀后浓缩至相对密度为1.26的稠膏,微波减压干燥,得到干浸膏,粉碎,过80目筛,即得。Weigh 30 parts of Bupleurum, 30 parts of Angelica, 30 parts of bran atractylodes, 20 parts of white peony, 10 parts of menthol, 15 parts of licorice, and add 8 times of 90% ethanol for 2 times, 2h each time. , filtered, the filtrate was combined, concentrated to a relative density of 1.10 alcohol extract paste; the drug residue was added to 8 times the weight of water for 2 times, each time 2h, filtered, the filtrate was combined, concentrated to a relative density of 1.10 water extract Clear the paste; add ethanol to the water extract paste to make the alcohol content up to 80%, let stand for 24h (4 ° C), take the supernatant to concentrate to a relative density of 1.10 clear paste, and mix with the alcohol extract paste, mix After concentration, it was concentrated to a thick paste having a relative density of 1.26, and dried under reduced pressure in a microwave to obtain a dry extract, which was pulverized and passed through a sieve of 80 mesh.
实施例4 抗抑郁药效实验Example 4 Antidepressant efficacy test
4.1实验动物4.1 experimental animals
SD成年雄性健康大鼠(北京维通利华实验动物技术有限公司,许可证号:SCXK(京)2014-0012)SD adult male healthy rat (Beijing Weitong Lihua Experimental Animal Technology Co., Ltd., license number: SCXK (Beijing) 2014-0012)
4.2实验药品与药材4.2 Experimental drugs and herbs
盐酸文拉法辛(成都康弘药业集团股份有限公司,规格:25mg/粒,批号:国药准字H20070269)Venlafaxine hydrochloride (Chengdu Kanghong Pharmaceutical Group Co., Ltd., specification: 25mg/granule, batch number: national medicine standard word H20070269)
舒肝解郁胶囊(成都康弘药业集团股份有限公司,规格:0.36g/粒,批号:国药准字Z20080580)Shugan Jieyu Capsule (Chengdu Kanghong Pharmaceutical Group Co., Ltd., Specification: 0.36g/granule, batch number: National Pharmaceutical Standard Z20080580)
实施例1制备的中药提取物,其中的柴胡、当归、麸炒白术、白芍、炙甘草和薄荷均购于山西省华阳药业有限公司,经山西大学中医药现代研究中心主任秦雪梅教授鉴定均为正品。The traditional Chinese medicine extract prepared in Example 1, wherein Bupleurum, Angelica, Bran White Atractylodes, Radix Paeoniae Alba, Radix Glycyrrhizae and Peppermint were purchased from Shanxi Huayang Pharmaceutical Co., Ltd., and Professor Qin Xuemei, Director of Modern Research Center of Traditional Chinese Medicine of Shanxi University The identification is genuine.
4.3动物分组及给药4.3 Animal grouping and administration
大鼠适应性饲养1周,期间进行糖水训练,根据体重将大鼠随机分为7组,每组10只。Rats were adaptively reared for 1 week, during which syrup training was carried out. Rats were randomly divided into 7 groups according to body weight, with 10 rats in each group.
①空白对照组(K)1 blank control group (K)
②模型组对照组(M)2 model group control group (M)
③文拉法辛组(35mg/kg)(Y)3 venlafaxine group (35mg/kg) (Y)
④舒肝解郁组(150mg/kg)(S)4 Shugan Jieyu group (150mg/kg)(S)
⑤中药提取物高剂量组(16.6g生药/kg)(G)5 Chinese medicine extract high dose group (16.6g crude drug / kg) (G)
⑥中药提取物中剂量组(8.3g生药/kg)(Z)6 Chinese medicine extract dose group (8.3g crude drug / kg) (Z)
⑦中药提取物低剂量组(4.2g生药/kg)(D)7 Chinese medicine extract low dose group (4.2g crude drug / kg) (D)
全部药物均用蒸馏水溶解,各组动物依据体重每天灌胃1次(1ml/100g)。All the drugs were dissolved in distilled water, and each group of animals was intragastrically administered once a day (1 ml/100 g) according to the body weight.
4.4模型建立4.4 Model establishment
刺激因子包括禁食、禁水、4℃冰水游泳、50℃热刺激、夹尾、间歇足底电击、束缚、超声刺激、昼夜颠倒。每日随机给予1种刺激,每种刺激累计使用2-3次。除空白对照组外,其余各组均单笼饲养并实施造模程序,造模时间为28d。造模开始后同时灌胃给药,药物组给予相应浓度药液,模型组及空白对照组给予等体积蒸馏水。Stimuli include fasting, water ban, 4°C ice water swimming, 50°C thermal stimulation, tail trapping, intermittent foot shock, restraint, ultrasound stimulation, and day and night reversal. One stimulus was randomly given daily, and each stimulus was used 2-3 times cumulatively. Except for the blank control group, the other groups were housed in a single cage and the modeling procedure was carried out. The modeling time was 28 days. After the start of modeling, the drug was administered by intragastric administration. The drug group was given the corresponding concentration of the drug solution, and the model group and the blank control group were given an equal volume of distilled water.
4.5检测指标4.5 detection indicators
体重:在实验第0、7、14、21、28d称量大鼠体重。Body weight: Rat body weight was weighed on the 0th, 7th, 14th, 21st, and 28th day of the experiment.
糖水偏爱率:造模结束后测定大鼠l%糖水消耗量,计算糖水偏爱率。Sugar water preference rate: After the end of modeling, the rat 1% sugar water consumption was measured, and the sugar water preference rate was calculated.
旷场实验:大鼠放入旷场箱5min,记录后4min内大鼠的穿格次数和直立次数。Open field experiment: Rats were placed in the open field box for 5 min, and the number of penetrating and erecting times of the rats within 4 min after recording were recorded.
4.6实验结果4.6 Experimental results
中药提取物对CUMS大鼠体重、糖水偏爱率和旷场实验等指标的影响由表1、2、3可知:中药提取物可以改善由CUMS造模应激引起的大鼠体重增长缓慢、在旷场实验中活动力降低和对蔗糖甜度的偏好下降,一定程度上表明中药提取物具有良好的抗抑郁作用,其药理活性达到或超过上市抗抑郁西药文拉法辛和抗抑郁中药舒肝解郁。The effects of Chinese herbal extracts on body weight, sucrose preference rate and open field test of CUMS rats are shown in Tables 1, 2 and 3: Chinese herbal extracts can improve the growth of rat body weight caused by CUMS modeling stress. In the field experiment, the decrease of activity and the preference for sucrose sweetness indicate that the extract of Chinese medicine has a good antidepressant effect, and its pharmacological activity meets or exceeds the listed antidepressant western medicine venlafaxine and antidepressant Chinese medicine Shugan solution. Yu.
与空白组相比#p<0.05,##p<0.01,与模型组相比*p<0.05,**p<0.01Compared with the blank group, #p<0.05, ##p<0.01, compared with the model group, *p<0.05, **p<0.01
表2 中药提取物对CUMS大鼠糖水偏爱率的影响
Table 2 Effect of Chinese herbal extracts on saccharide water preference rate in CUMS rats
与空白组相比#p<0.05,##p<0.01,与模型组相比*p<0.05,**p<0.01Compared with the blank group, #p<0.05, ##p<0.01, compared with the model group, *p<0.05, **p<0.01
与空白组相比#p<0.05,##p<0.01,与模型组相比*p<0.05,**p<0.01Compared with the blank group, #p<0.05, ##p<0.01, compared with the model group, *p<0.05, **p<0.01
实施例5 抗抑郁药效特点—改善CUMS抑郁大鼠胃肠功能研究Example 5 Antidepressant efficacy--Improvement of gastrointestinal function in CUMS depressed rats
5.1实验动物5.1 experimental animals
同实施例4。Same as Embodiment 4.
5.2实验药品与药材5.2 Experimental drugs and herbs
同实施例4。Same as Embodiment 4.
5.3动物分组及给药5.3 Animal grouping and administration
同实施例4。Same as Embodiment 4.
5.4模型建立5.4 Model establishment
同实施例4。Same as Embodiment 4.
5.5检测指标5.5 Test indicators
粪便:造模结束后,将实验各组大鼠放于代谢笼中,用塑料烧杯收集12h大鼠粪便,清点粪便数量,称重(湿重),用烘箱洪干(70℃,3h)再称重(干重)。计算粪便含水量=(湿重干重)/湿重×100%。Feces: After the modeling was completed, the rats in each group were placed in metabolic cages, and the feces of the rats were collected in a plastic beaker for 12 hours. The amount of feces was counted, weighed (wet weight), and dried in an oven (70 ° C, 3 h). Weighing (dry weight). Calculate the moisture content of the stool = (wet weight dry weight) / wet weight × 100%.
小肠推进和胃排空实验:处死前一天,禁食不禁水12h。次日在处死大鼠30min前根据1ml/100g剂量灌胃自制半固体营养糊,30min后处死大鼠,迅速解剖取出全胃,结扎胃贲门、胃幽门和回盲部,用滤纸擦干后称重得到胃全重(g)和小肠。用手术剪沿着胃壁的大弯剪开,用蒸馏水清洗胃内容物,滤纸擦干后称重得到胃净重(g)。Intestinal propulsion and gastric emptying experiments: The day before the death, fasting can not help but water for 12h. On the next day, 30 minutes before the rats were sacrificed, the self-made semi-solid nutrient paste was administered according to the dose of 1ml/100g. After 30 minutes, the rats were sacrificed, and the whole stomach was quickly dissected, and the gastric cardia, gastric pylorus and ileocecal part were ligated, and dried with filter paper. Regain total stomach weight (g) and small intestine. The surgical scissors were cut along the large curvature of the stomach wall, and the contents of the stomach were washed with distilled water, and the filter paper was dried and weighed to obtain the net weight (g) of the stomach.
胃内残留率=(胃全重-胃净重)/自制半固体营养糊重量×100%Gastric residual rate = (stomach weight - stomach net weight) / homemade semi-solid nutrient paste weight × 100%
小肠推进率=小肠全长/自制半固体糊推进处的距离×100%Small intestine propulsion rate = length of small intestine / distance of self-made semi-solid paste propulsion × 100%
5.6实验结果5.6 Experimental results
表4显示:CUMS应激使得大鼠的排便数量增加、粪便含水量下降。相比文拉法辛不能改善这一现象并呈现负调节情况,经中药提取物给药后可以改善上述指标的异常,表明中药提取物在改善CUMS大鼠抑郁样症状的同时,无引起粪便异常副作用。表5和6显示:造模应激减缓了大鼠的小肠蠕动和胃排空功能,文拉法辛相比模型组的小肠推进率和胃内餐路率有下降趋势,提示文拉法辛可能有着降低胃肠功能副作用,中药提取物可以在治疗抑郁症的同时改善大鼠胃肠功能。Table 4 shows that CUMS stress increases the number of bowel movements in rats and decreases the water content of feces. Compared with venlafaxine, this phenomenon can not be improved and negative regulation is observed. After the administration of traditional Chinese medicine extract, the abnormality of the above indicators can be improved, indicating that the Chinese herbal extract improves the depression-like symptoms of CUMS rats without causing fecal abnormalities. side effect. Tables 5 and 6 show that modeling stress slows the intestinal peristalsis and gastric emptying function in rats, and venlafaxine has a decreasing trend in the small intestine propulsion rate and intragastric meal rate compared with the model group, suggesting that venlafaxine It may have the effect of reducing gastrointestinal function. Chinese herbal extracts can improve gastrointestinal function in rats while treating depression.
与空白组相比#p<0.05,##p<0.01,与模型组相比*p<0.05,**p<0.01Compared with the blank group, #p<0.05, ##p<0.01, compared with the model group, *p<0.05, **p<0.01
表5 中药提取物对CUMS大鼠小肠推进率的影响
Table 5 Effect of Chinese Herb Extract on Small Intestinal Propulsion Rate in CUMS Rats
与空白组相比#p<0.05,##p<0.01,与模型组相比*p<0.05,**p<0.01Compared with the blank group, #p<0.05, ##p<0.01, compared with the model group, *p<0.05, **p<0.01
与空白组相比#p<0.05,##p<0.01,与模型组相比*p<0.05,**p<0.01Compared with the blank group, #p<0.05, ##p<0.01, compared with the model group, *p<0.05, **p<0.01
实施例6 抗抑郁药效特点—改善CUMS抑郁大鼠性功能研究Example 6 Antidepressant efficacy characteristics - improving sexual function in CUMS depressed rats
6.1实验动物6.1 experimental animals
同实施例4。Same as Embodiment 4.
6.2实验药品与药材6.2 Experimental drugs and herbs
同实施例4。Same as Embodiment 4.
6.3动物分组及给药6.3 Animal grouping and administration
同实施例4。Same as Embodiment 4.
6.4模型建立6.4 Model establishment
同实施例4。Same as Embodiment 4.
6.5检测指标6.5 test indicators
实验前48h,雌鼠皮下注射雌二醇10μg(溶于0.l ml红花油);实验前2h,皮下注射黄体酮10μg。将CUMS雄鼠和动情期雌鼠合笼,夜间7-9时,观察30min内雄鼠的性行为,记 录爬背潜伏期、爬背次数。48 h before the experiment, female mice were injected subcutaneously with estradiol 10 μg (dissolved in 0.1 ml safflower oil); 2 h before the experiment, 10 μg of progesterone was injected subcutaneously. The CUMS male and the estrus female were caged, and at 7-9 pm, the males' sexual behavior was observed within 30 minutes, and the crawling latency and the number of crawling backs were recorded.
6.6实验结果6.6 Experimental results
交配实验中雄鼠的爬背行为可以一定程度反映其性欲的大小。表7显示:CUMS应激使大鼠的爬背潜伏期延长、爬背次数减少,一定程度上反应大鼠性欲的唤醒收到造模应激的影响。相比文拉法辛对此指标呈现负调节,经中药提取物给药后可以改善上述指标的异常,表明中药提取物在改善CUMS大鼠抑郁样症状的同时,无引起性欲降低副作用。The crawling behavior of male rats in mating experiments can reflect the size of their sexual desire to a certain extent. Table 7 shows that CUMS stress prolongs the crawler latency of the rats and reduces the number of crawling backs. To some extent, the arousal of rat sexual desire is affected by the modeling stress. Compared with venlafaxine, this indicator is negatively regulated. After administration of traditional Chinese medicine extract, the abnormality of the above indicators can be improved, indicating that the Chinese herbal extract improves the depression-like symptoms of CUMS rats without causing side effects of libido reduction.
与空白组相比#p<0.05,##p<0.01,与模型组相比*p<0.05,**p<0.01Compared with the blank group, #p<0.05, ##p<0.01, compared with the model group, *p<0.05, **p<0.01
实施例7 抗抑郁药效特点—改善CUMS抑郁大鼠伴发学习记忆能力下降和焦虑情绪研究Example 7 Antidepressant efficacy--Improvement of learning and memory decline and anxiety in CUMS-depressed rats
7.1实验动物7.1 experimental animals
同实施例4。Same as Embodiment 4.
7.2实验药品与药材7.2 Experimental drugs and herbs
同实施例4。Same as Embodiment 4.
7.3动物分组及给药7.3 Animal grouping and administration
同实施例4。Same as Embodiment 4.
7.4模型建立7.4 Model establishment
同实施例4。Same as Embodiment 4.
7.5检测指标7.5 Test indicators
造模结束后进行Morris水迷宫和高架十字迷宫实验,选取水迷宫中的定位航行期空间搜索潜伏期和穿越平台次数作为对CUMS大鼠认知功能的考察;选取高架十字迷宫中的进入开放臂次数比例和进入开臂时间比例作为对CUMS大鼠焦虑情绪的考察。After the modeling, the Morris water maze and the elevated cross maze experiment were carried out. The spatial navigation latency and the number of crossing platforms in the water maze were selected as the investigation of the cognitive function of CUMS rats. The number of open arms in the elevated cross maze was selected. Proportion and ratio of time to open arm were used as an examination of anxiety in CUMS rats.
7.6实验结果7.6 Experimental results
表8显示:CUMS抑郁大鼠在空间探索期中穿越平台次数和目标象限路程减少,提示CUMS抑郁大鼠会伴有认知障碍的发生。相比文拉法辛不能调节这一现象,中药提取物给药后可以改善这一症状。Table 8 shows that CUMS-depressed rats have a reduced number of crossing platforms and target quadrants during the spatial exploration period, suggesting that CUMS-depressed rats are associated with cognitive impairment. Compared with venlafaxine, this phenomenon can be adjusted, and the Chinese herbal extract can improve this symptom after administration.
与空白组相比#p<0.05,##p<0.01,与模型组相比*p<0.05,**p<0.01Compared with the blank group, #p<0.05, ##p<0.01, compared with the model group, *p<0.05, **p<0.01
CUMS抑郁大鼠在高架十字迷宫中进入开壁时间比例和进入开壁次数比例减少,提示CUMS抑郁大鼠会伴有焦虑情绪的产生。文拉法辛和中药提取物给药后均可以改善这一症状。The proportion of CUMS-depressed rats entering the open time in the elevated plus maze and the proportion of entering the opening wall decreased, suggesting that CUMS depressed rats were associated with anxiety. Both venlafaxine and Chinese herbal extracts can improve this symptom after administration.
与空白组相比#p<0.05,##p<0.01,与模型组相比*p<0.05,**p<0.01Compared with the blank group, #p<0.05, ##p<0.01, compared with the model group, *p<0.05, **p<0.01
实施例8 无糖颗粒剂Example 8 Sugar-free granules
中药提取物粉末与预胶化淀粉以5:2的比例混合,采用干法制粒,制成颗粒,制粒时干法制粒机的参数调节为:挤压速度6.0rpm;送料速度7.0rpm;制粒速度10.0rpm;侧封压力13Mpa;挤压压力27Mpa。制粒时所用筛网的目数为10目,整粒筛网为40目。颗粒经过整粒,经复合膜包装后即得成品。The traditional Chinese medicine extract powder and the pregelatinized starch are mixed in a ratio of 5:2, and are granulated by dry granulation to prepare granules. The parameters of the dry granulator are adjusted to: extrusion speed 6.0 rpm; feed speed 7.0 rpm; The pellet speed was 10.0 rpm; the side seal pressure was 13 MPa; the extrusion pressure was 27 MPa. The mesh used in the granulation was 10 mesh, and the whole sieve was 40 mesh. The granules are granulated and packaged by the composite film to obtain the finished product.
实施例9 含糖颗粒剂Example 9 Sugar-containing granules
中药提取物粉末与蔗糖及糊精以2:0.5:0.5的比例混合,以75%乙醇为润湿剂,采用摇摆式制粒机,过10目不锈钢筛网制粒,干燥,过40目筛网整粒,采用复合膜包装即得。Chinese herbal extract powder is mixed with sucrose and dextrin in a ratio of 2:0.5:0.5, using 75% ethanol as a wetting agent, swaying granulator, passing through 10 mesh stainless steel mesh, granulating, drying, passing 40 mesh sieve The net is granulated and packaged in a composite film.
Claims (8)
- 一种具有抗抑郁功效的中药提取物,其特征在于中药组分配比和制备方法;An extract of traditional Chinese medicine having antidepressant effect, characterized by a distribution ratio and a preparation method of a traditional Chinese medicine group;所述中药组分按质量份数计为:柴胡20~60、当归20~60、麸炒白术20~60、白芍20~60、薄荷8~20、炙甘草8~20;The traditional Chinese medicine component is in terms of mass parts: Bupleurum 20-60, Angelica 20-60, bran-frying atractylodes 20-60, white peony 20-60, mint 8-20, licorice licorice 8-20;所述制备方法,包括如下步骤:1)在所述组分药材中加入6-10倍重量的60~90%乙醇提取2次,每次1-3h,滤过,合并滤液,浓缩得醇提清膏;2)药渣加入6-10倍重量的水提取2次,每次1-3h,滤过,合并滤液,浓缩得水提清膏,在水提清膏中加入乙醇使含醇量达60~80%,静置24h,取上清液,浓缩至清膏;3)将清膏与醇提清膏合并,混匀后浓缩至稠膏,微波减压干燥,粉碎过80目筛,即得中药提取物。The preparation method comprises the following steps: 1) adding 6-10 times weight of 60-90% ethanol to the component medicine, extracting twice, each time 1-3 h, filtering, combining the filtrate, and concentrating to obtain alcohol extract 2) The dregs are added with 6-10 times the weight of water for 2 times, each time 1-3h, filtered, the filtrate is combined, concentrated to obtain a water extracting paste, and ethanol is added to the water extracting paste to make the alcohol content Up to 60-80%, let stand for 24h, take the supernatant, concentrate to clear the paste; 3) combine the clear paste with the alcohol extract paste, mix and concentrate to thick paste, dry under microwave pressure, smash through 80 mesh sieve , that is, the Chinese medicine extract.
- 如权利要求1所述的中药提取物,其特征在于所述组分按质量份数计为:柴胡30、当归30、麸炒白术30、白芍30、薄荷10、炙甘草15。The traditional Chinese medicine extract according to claim 1, wherein said components are in parts by mass: Bupleurum 30, Angelica 30, Brassica chinensis 30, Angelica 30, Peppermint 10, and Zhigancao.
- 如权利要求1所述的中药提取物,其特征在于步骤1)中所述加入乙醇的重量为药材重量的8倍,乙醇浓度为75%,每次提取时间为2h。The traditional Chinese medicine extract according to claim 1, wherein the weight of the ethanol added in the step 1) is 8 times the weight of the medicinal material, the ethanol concentration is 75%, and the extraction time is 2 hours.
- 如权利要求1所述的中药提取物,其特征在于步骤2)中所述加入水的重量为药材重量的8倍,每次提取时间为2h。The traditional Chinese medicine extract according to claim 1, wherein the weight of the added water in the step 2) is 8 times the weight of the medicinal material, and the extraction time is 2 hours.
- 如权利要求1所述的中药提取物,其特征在于步骤3)中水提清膏加入乙醇后的含醇量为70%。The traditional Chinese medicine extract according to claim 1, characterized in that the alcohol content of the water extracting paste in step 3) after adding ethanol is 70%.
- 如权利要求1所述的中药提取物,其特征在于醇提清膏、水提清膏、清膏的密度控制在1.08~1.10,稠膏密度控制在1.24~1.26。The traditional Chinese medicine extract according to claim 1, wherein the density of the alcohol extracting paste, the water extracting paste and the clearing paste is controlled to be 1.08 to 1.10, and the density of the thick paste is controlled to be 1.24 to 1.26.
- 如权利要求1至6所述的中药提取物在制备治疗抑郁症药物中的应用。The use of the traditional Chinese medicine extract according to claims 1 to 6 for the preparation of a medicament for treating depression.
- 一种中药颗粒剂,含有如权利要求1至6任一所述的中药提取物。A traditional Chinese medicine granule comprising the traditional Chinese medicine extract according to any one of claims 1 to 6.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2019559814A JP6880236B2 (en) | 2017-10-12 | 2018-09-04 | Chinese herbal extract effective for depression and its preparation method and use |
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201710947004.4 | 2017-10-12 | ||
CN201710947004.4A CN107625813A (en) | 2017-10-12 | 2017-10-12 | A kind of Chinese medical extract with antidepression effect and its preparation method and application |
CN201810724541.7A CN108653405A (en) | 2017-10-12 | 2018-07-04 | A kind of Chinese medical extract and its preparation method and application with antidepression |
CN201810724541.7 | 2018-07-04 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2019072051A1 true WO2019072051A1 (en) | 2019-04-18 |
Family
ID=61105399
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/CN2018/103870 WO2019072051A1 (en) | 2017-10-12 | 2018-09-04 | Traditional chinese medicine extract with anti-depressive effect and preparation method and application thereof |
Country Status (3)
Country | Link |
---|---|
JP (1) | JP6880236B2 (en) |
CN (2) | CN107625813A (en) |
WO (1) | WO2019072051A1 (en) |
Cited By (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN111665107A (en) * | 2020-06-16 | 2020-09-15 | 湖南一方天江药业有限公司 | Extraction element is used in traditional chinese medicine experiment inspection convenient to ration is drawed |
WO2024168474A1 (en) * | 2023-02-13 | 2024-08-22 | 深圳先进技术研究院 | Analysis method and apparatus for comparing anti-anxiety effects of different drugs according to p values |
EP4190342A4 (en) * | 2020-07-30 | 2024-11-06 | Tasly Pharmaceutical Group Co., Ltd. | COMPOSITION OF TRADITIONAL CHINESE MEDICINE WITH MENTAL RELIEF AND ANTIDEPRESSANT EFFECT AND MANUFACTURING PROCESS THEREFOR |
Families Citing this family (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN111973692B (en) * | 2020-08-24 | 2022-01-21 | 江西普正制药股份有限公司 | Safflower Xiaoyao preparation, preparation method thereof and application thereof in depression resistance |
CN114191426B (en) * | 2021-11-12 | 2023-11-10 | 成都中医药大学 | A compound extract of Bupleurum Angelicae and Mint and its preparation method and use |
CN118001356A (en) * | 2024-01-29 | 2024-05-10 | 灿光医疗股份有限公司 | Anti-depression pharmaceutical composition and preparation method thereof |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1660403A (en) * | 2005-01-20 | 2005-08-31 | 北京勃然制药有限公司 | Carefree drop pills in use for soothing the liver and invigorating the spleen as well as enriching the blood and regulating menstruation, and preparing method |
CN101732427A (en) * | 2008-11-24 | 2010-06-16 | 广州白云山和记黄埔中药有限公司 | Medicinal composition for preventing and/or treating melancholia and climacteric syndrome |
-
2017
- 2017-10-12 CN CN201710947004.4A patent/CN107625813A/en active Pending
-
2018
- 2018-07-04 CN CN201810724541.7A patent/CN108653405A/en active Pending
- 2018-09-04 WO PCT/CN2018/103870 patent/WO2019072051A1/en active Application Filing
- 2018-09-04 JP JP2019559814A patent/JP6880236B2/en active Active
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1660403A (en) * | 2005-01-20 | 2005-08-31 | 北京勃然制药有限公司 | Carefree drop pills in use for soothing the liver and invigorating the spleen as well as enriching the blood and regulating menstruation, and preparing method |
CN101732427A (en) * | 2008-11-24 | 2010-06-16 | 广州白云山和记黄埔中药有限公司 | Medicinal composition for preventing and/or treating melancholia and climacteric syndrome |
Non-Patent Citations (1)
Title |
---|
HUANG, YANPING ET AL.: "Clinical Observation on 20 Cases of Post-Depression of Parkinson s Disease Treated by Combining the Xiaoyaosan and the Transcranial Magnetic Stimulation", FUJIAN JOURNAL OF TRADITIONAL CHINESE MEDICINE, vol. 47, no. 3, 30 June 2016 (2016-06-30), pages 51 * |
Cited By (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN111665107A (en) * | 2020-06-16 | 2020-09-15 | 湖南一方天江药业有限公司 | Extraction element is used in traditional chinese medicine experiment inspection convenient to ration is drawed |
EP4190342A4 (en) * | 2020-07-30 | 2024-11-06 | Tasly Pharmaceutical Group Co., Ltd. | COMPOSITION OF TRADITIONAL CHINESE MEDICINE WITH MENTAL RELIEF AND ANTIDEPRESSANT EFFECT AND MANUFACTURING PROCESS THEREFOR |
WO2024168474A1 (en) * | 2023-02-13 | 2024-08-22 | 深圳先进技术研究院 | Analysis method and apparatus for comparing anti-anxiety effects of different drugs according to p values |
Also Published As
Publication number | Publication date |
---|---|
CN108653405A (en) | 2018-10-16 |
CN107625813A (en) | 2018-01-26 |
JP6880236B2 (en) | 2021-06-02 |
JP2020518596A (en) | 2020-06-25 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO2019072051A1 (en) | Traditional chinese medicine extract with anti-depressive effect and preparation method and application thereof | |
CN102225138B (en) | Traditional Chinese medicine composition for treating fracture and preparation method and application thereof | |
CN104758953A (en) | Gastrointestinal tract contrast agent | |
CN102302692A (en) | Traditional Chinese medicine composition for treating constipation, as well as preparation method and application thereof | |
CN106031772A (en) | Composition having sleep improving function, and preparation method thereof | |
CN103007063B (en) | Medicinal composition for treating facial paralysis and preparation method thereof | |
CN106539908A (en) | A kind of Chinese medicine composition for treating allergic rhinitises and skin allergy | |
CN101780124B (en) | A kind of Lonely Thousand Miles Extract and its preparation method and application | |
CN101890062A (en) | Application of nard pine and its extract in the preparation of medicine for treating gastric ulcer | |
CN103768327B (en) | A kind of pure component Chinese medicine preparation and preparation technology treating functional dyspepsia | |
CN104042713A (en) | Traditional Chinese medicine composition for treating bronchial asthma | |
CN103028071A (en) | Traditional Chinese medicine composition for treating diarrhea-dominant irritable bowel syndrome and preparation method of traditional Chinese medicine composition | |
CN106581214A (en) | Ischemic stroke treating traditional Chinese medicine composition and preparation method thereof | |
CN101406556B (en) | Chinese medicine preparation for treating acute prostatitis, prostatic hyperplasia and preparation method thereof | |
CN101524447A (en) | Pharmaceutical composition for treating constipation and preparation process thereof | |
CN104435079A (en) | Traditional Chinese medicinal composition for treating gout | |
CN100484561C (en) | Medicament composition for treating ulcer in alimentary canal and preparation method | |
CN103495071A (en) | Capsule for treating neurosis intestinal obstruction after gastrointestinal surgery and preparation method thereof | |
CN102961678B (en) | Traditional Chinese medicine preparation for treating gallstone and cholecystitis and preparation method thereof | |
CN107638453A (en) | Scorching graceful particle of a kind of woman and preparation method thereof | |
CN104888050A (en) | Drug for treating constipation | |
CN116270949A (en) | Traditional Chinese medicine composition for reducing hyperuricemia and preparation method thereof | |
CN106039210A (en) | Traditional Chinese medicinal composition for treating hyperplasia of mammary glands as well as preparation method and application thereof | |
CN102940659B (en) | An effective part of Atractylodes macrocephala for treating constipation of spleen deficiency type | |
CN105126003A (en) | Traditional Chinese medicine composition for preventing and curing madness and preparation method |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 18866828 Country of ref document: EP Kind code of ref document: A1 |
|
ENP | Entry into the national phase |
Ref document number: 2019559814 Country of ref document: JP Kind code of ref document: A |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
122 | Ep: pct application non-entry in european phase |
Ref document number: 18866828 Country of ref document: EP Kind code of ref document: A1 |